Shares of Pharming Group (NASDAQ:PHAR – Get Free Report) were up 5.6% during trading on Monday . The company traded as high as $7.98 and last traded at $7.98. Approximately 1,812 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 4,405 shares. The stock had previously closed at $7.56.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.
View Our Latest Stock Analysis on PHAR
Pharming Group Stock Up 4.1 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same period last year, the company earned $0.02 earnings per share. Analysts forecast that Pharming Group will post -0.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- About the Markup Calculator
- Sleeper AI-Winner Ambarella Will More Than Triple in Price
- ESG Stocks, What Investors Should Know
- Gold vs. Silver: Which Is the Better Investment in the New Cycle?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Best Growth Stocks to Own for the Next 10 Years
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.